I welcome the development of the anemia drugs. We have luspatercept in phase 3, fully accrued, awaiting those results. We have DISC-0974, the anti-hemojuvelin — very exciting — as well as ...

"Receiving Orphan Drug Designation for CK0801 in Aplastic Anemia underscores the importance ... are designed to provide powerful anti-inflammatory effects and long-lasting immune modulation ...

An anemia drug developed under an alliance between FibroGen and AstraZeneca will continue its commercialization in China fully in the hands of the pharmaceutical giant, which is buying the China ...

The use of Siddha drug treatment can help reduce anemia among adolescent girls as per a study that highlights the potential of traditional medicine in improving adolescent health (1 Trusted ...

Akebia Therapeutics is preparing for a January 2025 launch of its anemia drug Vafseo for patients on dialysis. The drug maker plans to reopened talks with the FDA about the pre-dialysis population.

They might also experience sickle cell anemia, as sickle cells only last ... Other treatments for sickle cell disease include anti-sickling medications and new genetic therapies.

Secondary AIHA: Secondary AIHA develops in response to an underlying condition, such as an autoimmune disorder, cancer, infection, or certain medications. Autoimmune hemolytic anemia symptoms vary ...

For older individuals, treatment of aplastic anemia focuses on suppressing the immune system with Atgam (anti-thymocyte globulin) and Sandimmune (cyclosporine), along with Promacta (eltrombopag), a ...

Emerging novel classes of anti-anemic drugs recently introduced or in development for other types of anemia include activin receptor ligand traps, hypoxia-inducible factor-prolyl hydroxylase ...

March 27 (Reuters) - The U.S. Food and Drug Administration approved Akebia Therapeutics' (AKBA.O), opens new tab drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in ...